Furthermore, the association of different PARP inhibitors such as niraparib and olaparib with cisplatin also induced additive effects on the treatment of LC and in other cancer types, namely cervical, liver, and testicular cancer [23,24,26,27,28]. The gene discussed is PARP1; the disease is cancer.